Major Complications following Hematopoietic Stem Cell Transplantation

ABSTRACT

Tens of thousands of patients undergo hematopoietic stem cell transplantation (HSCT) annually, 15 to 40% of whom are admitted to the intensive care unit. Pulmonary complications are the most life threatening conditions that develop in HSCT recipients. Both infectious and noninfectious complications occur more frequently in allogeneic HSCT. The management of HSCT recipients requires knowledge of their immune status, appropriate diagnostic evaluation, and early treatment. During the preengraftment phase (0 to 30 days after transplant), the most prevalent pathogens causing infection are bacteria and Candida species and, if the neutropenia persists, Aspergillus species. The early postengraftment phase (30 to 100 days) is characterized by cytomegalovirus (CMV), Pneumocystis jiroveci, and Aspergillus infections. During the late posttransplant phase (> 100 days), allogeneic HSCT recipients are at risk for CMV, community-acquired respiratory virus, and encapsulated bacterial infections. Antigen and polymerase chain reaction assays are important for the diagnosis of CMV and Aspergillus infections. Diffuse alveolar hemorrhage (DAH) and periengraftment respiratory distress syndrome occur in both allogeneic and autologous HSCT recipients, usually during the first 30 days. Bronchiolitis obliterans occurs exclusively in allogeneic HSCT recipients with graft versus host disease. Idiopathic pneumonia syndrome occurs at any time following transplant. Bronchoscopy is usually helpful for the diagnosis of the infectious pulmonary complications and DAH.

Aspergillosis - bone marrow transplantation - cytomegalovirus infection - diffuse alveolar hemorrhage - idiopathic pneumonia syndrome - periengraftment respiratory distress syndrome - pneumonia - respiratory insufficiency

REFERENCES

• 1 Report on state of the art in blood and marrow transplantation.  IBMTR/ABMTR Newsletter. 2003;  10 7-10
• 2 Afessa B, Tefferi A, Hoagland H C, Letendre L, Peters S G. Outcome of recipients of bone marrow transplants who require intensive care unit support.  Mayo Clin Proc. 1992;  67 117-122
• 3 Afessa B, Tefferi A, Dunn W F, Litzow M R, Peters S G. Intensive care unit support and Acute Physiology and Chronic Health Evaluation III performance in hematopoietic stem cell transplant recipients.  Crit Care Med. 2003;  31 1715-1721
• 4 Jackson S R, Tweeddale M G, Barnett M J et al.. Admission of bone marrow transplant recipients to the intensive care unit: outcome, survival and prognostic factors.  Bone Marrow Transplant. 1998;  21 697-704
• 5 Crawford S W, Petersen F B. Long-term survival from respiratory failure after marrow transplantation for malignancy.  Am Rev Respir Dis. 1992;  145 510-514
• 6 Khassawneh B Y, White Jr P, Anaissie E J, Barlogie B, Hiller F C. Outcome from mechanical ventilation after autologous peripheral blood stem cell transplantation.  Chest. 2002;  121 185-188
• 7 Scott P H, Morgan T J, Durrant S, Boots R J. Survival following mechanical ventilation of recipients of bone marrow transplants and peripheral blood stem cell transplants.  Anaesth Intensive Care. 2002;  30 289-294
• 8 Matulis M, High K P. Immune reconstitution after hematopoietic stem-cell transplantation and its influence on respiratory infections.  Semin Respir Infect. 2002;  17 130-139
• 9 Gosselin M V, Adams R H. Pulmonary complications in bone marrow transplantation.  J Thorac Imaging. 2002;  17 132-144
• 10 Ninin E, Milpied N, Moreau P et al.. Longitudinal study of bacterial, viral, and fungal infections in adult recipients of bone marrow transplants.  Clin Infect Dis. 2001;  33 41-47
• 11 George B, Mathews V, Srivastava A, Chandy M. Infections among allogeneic bone marrow transplant recipients in India.  Bone Marrow Transplant. 2004;  33 311-315
• 12 Yoo J H, Lee D G, Choi S M et al.. Infectious complications and outcomes after allogeneic hematopoietic stem cell transplantation in Korea.  Bone Marrow Transplant. 2004;  34 497-504
• 13 Afessa B, Litzow M R, Tefferi A. Bronchiolitis obliterans and other late onset noninfectious pulmonary complications in hematopoietic stem cell transplantation.  Bone Marrow Transplant. 2001;  28 425-434
• 14 Hughes W T, Armstrong D, Bodey G P et al.. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer.  Clin Infect Dis. 2002;  34 730-751
• 15 Feinstein M B, Mokhtari M, Ferreiro R, Stover D E, Jakubowski A. Fiberoptic bronchoscopy in allogeneic bone marrow transplantation: findings in the era of serum cytomegalovirus antigen surveillance.  Chest. 2001;  120 1094-1100
• 16 Leung A N, Gosselin M V, Napper C H et al.. Pulmonary infections after bone marrow transplantation: clinical and radiographic findings.  Radiology. 1999;  210 699-710
• 17 Patel N R, Lee P S, Kim J H, Weinhouse G L, Koziel H. The influence of diagnostic bronchoscopy on clinical outcomes comparing adult autologous and allogeneic bone marrow transplant patients.  Chest. 2005;  127 1388-1396
• 18 Taplitz R A, Jordan M C. Pneumonia caused by herpesviruses in recipients of hematopoietic cell transplants.  Semin Respir Infect. 2002;  17 121-129
• 19 Ebbert J O, Limper A H. Respiratory syncytial virus pneumonitis in immunocompromised adults: clinical features and outcome.  Respiration . 2005;  72 263-269
• 20 Ghosh S, Champlin R E, Englund J et al.. Respiratory syncytial virus upper respiratory tract illnesses in adult blood and marrow transplant recipients: combination therapy with aerosolized ribavirin and intravenous immunoglobulin.  Bone Marrow Transplant. 2000;  25 751-755
• 21 Atkinson K, Nivison-Smith I, Dodds A, Concannon A, Milliken S, Downs K. A comparison of the pattern of interstitial pneumonitis following allogeneic bone marrow transplantation before and after the introduction of prophylactic ganciclovir therapy in 1989.  Bone Marrow Transplant. 1998;  21 691-695
• 22 Ibrahim A, Gautier E, Roittmann S et al.. Should cytomegalovirus be tested for in both blood and bronchoalveolar lavage fluid of patients at a high risk of CMV pneumonia after bone marrow transplantation?.  Br J Haematol. 1997;  98 222-227
• 23 Sakuma H, Hosoya M, Kanno H et al.. Risk of cytomegalovirus infection after peripheral blood stem cell transplantation.  Bone Marrow Transplant. 1997;  19 49-53
• 24 Yanada M, Yamamoto K, Emi N et al.. Cytomegalovirus antigenemia and outcome of patients treated with preemptive ganciclovir: retrospective analysis of 241 consecutive patients undergoing allogeneic hematopoietic stem cell transplantation.  Bone Marrow Transplant. 2003;  32 801-807
• 25 Enright H, Haake R, Weisdorf D et al.. Cytomegalovirus pneumonia after bone marrow transplantation: risk factors and response to therapy.  Transplantation. 1993;  55 1339-1346
• 26 Zekri A R, Mohamed W S, Samra M A, Sherif G M, El Shehaby A M, El Sayed M H. Risk factors for cytomegalovirus, hepatitis B and C virus reactivation after bone marrow transplantation.  Transpl Immunol. 2004;  13 305-311
• 27 Kim D H, Kim J G, Lee N Y et al.. Risk factors for late cytomegalovirus infection after allogeneic stem cell transplantation using HLA-matched sibling donor: donor lymphocyte infusion and previous history of early CMV infection.  Bone Marrow Transplant. 2004;  34 21-27
• 28 Morfin F, Boucher A, Najioullah F et al.. Cytomegalovirus and adenovirus infections and diseases among 75 paediatric unrelated allogeneic bone marrow transplant recipients.  J Med Virol. 2004;  72 257-262
• 29 Gasparetto E L, Ono S E, Escuissato D et al.. Cytomegalovirus pneumonia after bone marrow transplantation: high resolution CT findings.  Br J Radiol. 2004;  77 724-727
• 30 Machado C M, Dulley F L, Boas L S et al.. CMV pneumonia in allogeneic BMT recipients undergoing early treatment of preemptive ganciclovir therapy.  Bone Marrow Transplant. 2000;  26 413-417
• 31 Konoplev S, Champlin R E, Giralt S et al.. Cytomegalovirus pneumonia in adult autologous blood and marrow transplant recipients.  Bone Marrow Transplant. 2001;  27 877-881
• 32 Wah T M, Moss H A, Robertson R J, Barnard D L. Pulmonary complications following bone marrow transplantation.  Br J Radiol. 2003;  76 373-379
• 33 Escuissato D L, Gasparetto E L, Marchiori E et al.. Pulmonary infections after bone marrow transplantation: high-resolution CT findings in 111 patients.  AJR Am J Roentgenol. 2005;  185 608-615
• 34 Boeckh M, Boivin G. Quantitation of cytomegalovirus: methodologic aspects and clinical applications.  Clin Microbiol Rev. 1998;  11 533-554
• 35 Ljungman P, De Bock R, Cordonnier C et al.. Practices for cytomegalovirus diagnosis, prophylaxis and treatment in allogeneic bone marrow transplant recipients: a report from the Working Party for Infectious Diseases of the EBMT.  Bone Marrow Transplant. 1993;  12 399-403
• 36 Shelhamer J H, Gill V J, Quinn T C et al.. The laboratory evaluation of opportunistic pulmonary infections.  Ann Intern Med. 1996;  124 585-599
• 37 Sokos D R, Berger M, Lazarus H M. Intravenous immunoglobulin: appropriate indications and uses in hematopoietic stem cell transplantation.  Biol Blood Marrow Transplant. 2002;  8 117-130
• 38 Limaye A P, Bowden R A, Myerson D, Boeckh M. Cytomegalovirus disease occurring before engraftment in marrow transplant recipients.  Clin Infect Dis. 1997;  24 830-835
• 39 Nguyen Q, Champlin R, Giralt S et al.. Late cytomegalovirus pneumonia in adult allogeneic blood and marrow transplant recipients.  Clin Infect Dis. 1999;  28 618-623
• 40 Chen C S, Boeckh M, Seidel K et al.. Incidence, risk factors, and mortality from pneumonia developing late after hematopoietic stem cell transplantation.  Bone Marrow Transplant. 2003;  32 515-522
• 41 Marr K A, Bowden R A. Fungal infections in patients undergoing blood and marrow transplantation.  Transpl Infect Dis. 1999;  1 237-246
• 42 Marr K A, Carter R A, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors.  Blood. 2002;  100 4358-4366
• 43 Oliveira J S, Kerbauy F R, Colombo A L et al.. Fungal infections in marrow transplant recipients under antifungal prophylaxis with fluconazole.  Braz J Med Biol Res. 2002;  35 789-798
• 44 Wakayama M, Shibuya K, Ando T et al.. Deep-seated mycosis as a complication in bone marrow transplantation patients.  Mycoses. 2002;  45 146-151
• 45 Ascioglu S, Rex J H, de Pauw B et al.. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus.  Clin Infect Dis. 2002;  34 7-14
• 46 Grow W B, Moreb J S, Roque D et al.. Late onset of invasive Aspergillus infection in bone marrow transplant patients at a university hospital.  Bone Marrow Transplant. 2002;  29 15-19
• 47 Soubani A O, Qureshi M A. Invasive pulmonary aspergillosis following bone marrow transplantation: risk factors and diagnostic aspect.  Haematologia (Budap). 2002;  32 427-437
• 48 Soubani A O, Chandrasekar P H. The clinical spectrum of pulmonary aspergillosis.  Chest. 2002;  121 1988-1999
• 49 Horger M, Einsele H, Schumacher U et al.. Invasive pulmonary aspergillosis: frequency and meaning of the “hypodense sign” on unenhanced CT.  Br J Radiol. 2005;  78 697-703
• 50 Bialek R, Moshous D, Casanova J L, Blanche S, Hennequin C. Aspergillus antigen and PCR assays in bone marrow transplanted children.  Eur J Med Res. 2002;  7 177-180
• 51 Stevens D A, Kan V L, Judson M A et al.. Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America.  Clin Infect Dis. 2000;  30 696-709
• 52 Centers for Disease Control and Prevention . Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Recommendations of CDC, the Infectious Disease Society of America, and the American Society of Blood and Marrow Transplantation.  MMWR. 2000;  49(No. RR-10) 1-128
• 53 Kruger W H, Zollner B, Kaulfers P M, Zander A R. Effective protection of allogeneic stem cell recipients against aspergillosis by HEPA air filtration during a period of construction: a prospective survey.  J Hematother Stem Cell Res. 2003;  12 301-307
• 54 Schwartz S, Behre G, Heinemann V et al.. Aerosolized amphotericin B inhalations as prophylaxis of invasive aspergillus infections during prolonged neutropenia: results of a prospective randomized multicenter trial.  Blood. 1999;  93 3654-3661
• 55 Grigg A. Prophylaxis and treatment of patients with aspergillosis: an overview, including the Royal Melbourne Hospital experience.  J Antimicrob Chemother. 2002;  49(Suppl 1) 75-80
• 56 Oren I, Haddad N, Finkelstein R, Rowe J M. Invasive pulmonary aspergillosis in neutropenic patients during hospital construction: before and after chemoprophylaxis and institution of HEPA filters.  Am J Hematol. 2001;  66 257-262
• 57 Wilkin A, Feinberg J. Prophylaxis against fungal infections and cytomegalovirus disease after bone marrow transplantation.  Oncology. 2000;  14 1701-1708
• 58 Lin S J, Schranz J, Teutsch S M. Aspergillosis case-fatality rate: systematic review of the literature.  Clin Infect Dis. 2001;  32 358-366
• 59 Roychowdhury M, Pambuccian S E, Aslan D L et al.. Pulmonary complications after bone marrow transplantation: an autopsy study from a large transplantation center.  Arch Pathol Lab Med. 2005;  129 366-371
• 60 Sharma S, Nadrous H F, Peters S G et al.. Pulmonary complications in adult blood and marrow transplant recipients: autopsy findings.  Chest. 2005;  128 1385-1392
• 61 Soubani A O, Qureshi M A, Baynes R D. Flexible bronchoscopy in the diagnosis of pulmonary infiltrates following autologous peripheral stem cell transplantation for advanced breast cancer.  Bone Marrow Transplant. 2001;  28 981-985
• 62 Springmeyer S C, Silvestri R C, Sale G E et al.. The role of transbronchial biopsy for the diagnosis of diffuse pneumonias in immunocompromised marrow transplant recipients.  Am Rev Respir Dis. 1982;  126 763-765
• 63 Goodrich J M, Reed E C, Mori M et al.. Clinical features and analysis of risk factors for invasive candidal infection after marrow transplantation.  J Infect Dis. 1991;  164 731-740
• 64 Verfaillie C, Weisdorf D, Haake R, Hostetter M, Ramsay N K, McGlave P. Candida infections in bone marrow transplant recipients.  Bone Marrow Transplant. 1991;  8 177-184
• 65 Collin B A, Leather H L, Wingard J R, Ramphal R. Evolution, incidence, and susceptibility of bacterial bloodstream isolates from 519 bone marrow transplant patients.  Clin Infect Dis. 2001;  33 947-953
• 66 Lossos I S, Breuer R, Or R et al.. Bacterial pneumonia in recipients of bone marrow transplantation: a five-year prospective study.  Transplantation. 1995;  60 672-678
• 67 Ramphal R. Changes in the etiology of bacteremia in febrile neutropenic patients and the susceptibilities of the currently isolated pathogens.  Clin Infect Dis. 2004;  39(Suppl 1) S25-S31
• 68 Kruger W H, Bohlius J, Cornely O A et al.. Antimicrobial prophylaxis in allogeneic bone marrow transplantation. Guidelines of the infectious diseases working party (AGIHO) of the German Society of Haematology and Oncology.  Ann Oncol. 2005;  16 1381-1390
• 69 Cahill R A, Spitzer T R, Mazumder A. Marrow engraftment and clinical manifestations of capillary leak syndrome.  Bone Marrow Transplant. 1996;  18 177-184
• 70 Dickout W J, Chan C K, Hyland R H et al.. Prevention of acute pulmonary edema after bone marrow transplantation.  Chest. 1987;  92 303-309
• 71 Snowden J A, Hill G R, Hunt P et al.. Assessment of cardiotoxicity during haemopoietic stem cell transplantation with plasma brain natriuretic peptide.  Bone Marrow Transplant. 2000;  26 309-313
• 72 Wong R, Rondon G, Saliba R M et al.. Idiopathic pneumonia syndrome after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for high-risk breast cancer.  Bone Marrow Transplant. 2003;  31 1157-1163
• 73 Clark J G, Hansen J A, Hertz M I, Parkman R, Jensen L, Peavy H H. NHLBI workshop summary: idiopathic pneumonia syndrome after bone marrow transplantation.  Am Rev Respir Dis. 1993;  147 1601-1606
• 74 Hauber H P, Mikkila A, Erich J M et al.. TNF-alpha, interleukin-10 and interleukin-18 expression in cells of the bronchoalveolar lavage in patients with pulmonary complications following bone marrow or peripheral stem cell transplantation: a preliminary study.  Bone Marrow Transplant. 2002;  30 485-490
• 75 Schots R, Kaufman L, Van R I et al.. Proinflammatory cytokines and their role in the development of major transplant-related complications in the early phase after allogeneic bone marrow transplantation.  Leukemia. 2003;  17 1150-1156
• 76 Yanik G, Hellerstedt B, Custer J et al.. Etanercept (Enbrel) administration for idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation.  Biol Blood Marrow Transplant. 2002;  8 395-400
• 77 Kantrow S P, Hackman R C, Boeckh M, Myerson D, Crawford S W. Idiopathic pneumonia syndrome: changing spectrum of lung injury after marrow transplantation.  Transplantation. 1997;  63 1079-1086
• 78 Afessa B, Tefferi A, Litzow M R, Krowka M J, Wylam M E, Peters S G. Diffuse alveolar hemorrhage in hematopoietic stem cell transplant recipients.  Am J Respir Crit Care Med. 2002;  166 641-645
• 79 Capizzi S A, Kumar S, Huneke N E et al.. Periengraftment respiratory distress syndrome during autologous hematopoietic stem cell transplantation.  Bone Marrow Transplant. 2001;  27 1299-1303
• 80 Griese M, Rampf U, Hofmann D, Fuhrer M, Reinhardt D, Bender-Gotze C. Pulmonary complications after bone marrow transplantation in children: twenty-four years of experience in a single pediatric center.  Pediatr Pulmonol. 2000;  30 393-401
• 81 Crawford S W, Hackman R C. Clinical course of idiopathic pneumonia after bone marrow transplantation.  Am Rev Respir Dis. 1993;  147 1393-1400
• 82 Robbins R A, Linder J, Stahl M G et al.. Diffuse alveolar hemorrhage in autologous bone marrow transplant recipients.  Am J Med. 1989;  87 511-518
• 83 Afessa B, Tefferi A, Litzow M R, Peters S G. Outcome of diffuse alveolar hemorrhage in hematopoietic stem cell transplant recipients.  Am J Respir Crit Care Med. 2002;  166 1364-1368
• 84 Witte R J, Gurney J W, Robbins R A et al.. Diffuse pulmonary alveolar hemorrhage after bone marrow transplantation: radiographic findings in 39 patients.  AJR Am J Roentgenol. 1991;  157 461-464
• 85 Hicks K, Peng D, Gajewski J L. Treatment of diffuse alveolar hemorrhage after allogeneic bone marrow transplant with recombinant factor VIIa.  Bone Marrow Transplant. 2002;  30 975-978
• 86 Pastores S M, Papadopoulos E, Voigt L, Halpern N A. Diffuse alveolar hemorrhage after allogeneic hematopoietic stem-cell transplantation: treatment with recombinant factor VIIa.  Chest. 2003;  124 2400-2403
• 87 Lewis I D, DeFor T, Weisdorf D J. Increasing incidence of diffuse alveolar hemorrhage following allogeneic bone marrow transplantation: cryptic etiology and uncertain therapy.  Bone Marrow Transplant. 2000;  26 539-543
• 88 Metcalf J P, Rennard S I, Reed E C et al.. Corticosteroids as adjunctive therapy for diffuse alveolar hemorrhage associated with bone marrow transplantation. University of Nebraska Medical Center Bone Marrow Transplant Group.  Am J Med. 1994;  96 327-334
• 89 Akasheh M, Eastwood D, Vesole D H. Engraftment syndrome after autologous hematopoietic stem cell transplant supported by granulocyte-colony-stimulating factor (G-CSF) versus granulocyte-macrophage colony-stimulating factor (GM-CSF).  Bone Marrow Transplant. 2003;  31 113-116
• 90 Maiolino A, Biasoli I, Lima J, Portugal A C, Pulcheri W, Nucci M. Engraftment syndrome following autologous hematopoietic stem cell transplantation: definition of diagnostic criteria.  Bone Marrow Transplant. 2003;  31 393-397
• 91 Carlens S, Ringden O, Remberger M et al.. Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis.  Bone Marrow Transplant. 1998;  22 755-761
• 92 Holland H K, Wingard J R, Beschorner W E, Saral R, Santos G W. Bronchiolitis obliterans in bone marrow transplantation and its relationship to chronic graft-v-host disease and low serum IgG.  Blood. 1988;  72 621-627
• 93 Clark J G, Crawford S W, Madtes D K, Sullivan K M. Obstructive lung disease after allogeneic marrow transplantation: clinical presentation and course.  Ann Intern Med. 1989;  111 368-376
• 94 St. John R C, Gadek J E, Tutschka P J, Kapoor N, Dorinsky P M. Analysis of airflow obstruction by bronchoalveolar lavage following bone marrow transplantation. Implications for pathogenesis and treatment.  Chest. 1990;  98 600-607
• 95 Crawford S W, Clark J G. Bronchiolitis associated with bone marrow transplantation.  Clin Chest Med. 1993;  14 741-749
• 96 Khalid M, Al Saghir A, Saleemi S et al.. Azithromycin in bronchiolitis obliterans complicating bone marrow transplantation: a preliminary study.  Eur Respir J. 2005;  25 490-493
• 97 Favaloro R, Bertolotti A, Gomez C et al.. Lung transplant at the Favaloro Foundation: a 13-year experience.  Transplant Proc. 2004;  36 1689-1691
• 98 Dudek A Z, Mahaseth H, DeFor T E, Weisdorf D J. Bronchiolitis obliterans in chronic graft-versus-host disease: analysis of risk factors and treatment outcomes.  Biol Blood Marrow Transplant. 2003;  9 657-666
• 99 Hayes-Jordan A, Benaim E, Richardson S et al.. Open lung biopsy in pediatric bone marrow transplant patients.  J Pediatr Surg. 2002;  37 446-452
• 100 Kanamori H, Fujisawa S, Tsuburai T et al.. Increased exhaled nitric oxide in bronchiolitis obliterans organizing pneumonia after allogeneic bone marrow transplantation.  Transplantation. 2002;  74 1356-1358
• 101 Alasaly K, Muller N, Ostrow D N, Champion P, FitzGerald J M. Cryptogenic organizing pneumonia: a report of 25 cases and a review of the literature.  Medicine (Baltimore). 1995;  74 201-211
• 102 Myers J L, Colby T V. Pathologic manifestations of bronchiolitis, constrictive bronchiolitis, cryptogenic organizing pneumonia, and diffuse panbronchiolitis.  Clin Chest Med. 1993;  14 611-622
• 103 Ishii T, Manabe A, Ebihara Y et al.. Improvement in bronchiolitis obliterans organizing pneumonia in a child after allogeneic bone marrow transplantation by a combination of oral prednisolone and low dose erythromycin.  Bone Marrow Transplant. 2000;  26 907-910
• 104 Pedrazzoli P, Ferrante P, Kulekci A et al.. Autologous hematopoietic stem cell transplantation for breast cancer in Europe: critical evaluation of data from the European Group for Blood and Marrow Transplantation (EBMT) Registry 1990-1999.  Bone Marrow Transplant. 2003;  32 489-494
• 105 Bhalla K S, Wilczynski S W, Abushamaa A M et al.. Pulmonary toxicity of induction chemotherapy prior to standard or high- dose chemotherapy with autologous hematopoietic support.  Am J Respir Crit Care Med. 2000;  161 17-25
• 106 Cao T M, Negrin R S, Stockerl-Goldstein K E et al.. Pulmonary toxicity syndrome in breast cancer patients undergoing BCNU-containing high-dose chemotherapy and autologous hematopoietic cell transplantation.  Biol Blood Marrow Transplant. 2000;  6 387-394
• 107 Chap L, Shpiner R, Levine M, Norton L, Lill M, Glaspy J. Pulmonary toxicity of high-dose chemotherapy for breast cancer: a noninvasive approach to diagnosis and treatment.  Bone Marrow Transplant. 1997;  20 1063-1067
• 108 Stadtmauer E A, O'Neill A, Goldstein L J et al.. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group.  N Engl J Med. 2000;  342 1069-1076
• 109 Wilczynski S W, Erasmus J J, Petros W P, Vredenburgh J J, Folz R J. Delayed pulmonary toxicity syndrome following high-dose chemotherapy and bone marrow transplantation for breast cancer.  Am J Respir Crit Care Med. 1998;  157 565-573
• 110 Suratt B T, Lynch D A, Cool C D, Jones R B, Brown K K. Interferon-gamma for delayed pulmonary toxicity syndrome resistant to steroids.  Bone Marrow Transplant. 2003;  31 939-941
• 111 McGaughey D S, Nikcevich D A, Long G D et al.. Inhaled steroids as prophylaxis for delayed pulmonary toxicity syndrome in breast cancer patients undergoing high-dose chemotherapy and autologous stem cell transplantation.  Biol Blood Marrow Transplant. 2001;  7 274-278
• 112 Gulbahce H E, Pambuccian S E, Jessurun J et al.. Pulmonary nodular lesions in bone marrow transplant recipients: impact of histologic diagnosis on patient management and prognosis.  Am J Clin Pathol. 2004;  121 205-210
• 113 Morales I J, Anderson P M, Tazelaar H D, Wylam M E. Pulmonary cytolytic thrombi: unusual complication of hematopoietic stem cell transplantation.  J Pediatr Hematol Oncol. 2003;  25 89-92
• 114 Gulbahce H E, Manivel J C, Jessurun J. Pulmonary cytolytic thrombi: a previously unrecognized complication of bone marrow transplantation.  Am J Surg Pathol. 2000;  24 1147-1152
• 115 Woodard J P, Gulbahce E, Shreve M et al.. Pulmonary cytolytic thrombi: a newly recognized complication of stem cell transplantation.  Bone Marrow Transplant. 2000;  25 293-300